WallStreetZenWallStreetZen

NASDAQ: KPTI
Karyopharm Therapeutics Inc Stock

$1.19+0.03 (+2.59%)
Updated Mar 1, 2024
KPTI Price
$1.19
Fair Value Price
N/A
Market Cap
$136.35M
52 Week Low
$0.62
52 Week High
$4.87
P/E
-0.95x
P/B
-1x
P/S
0.68x
PEG
N/A
Dividend Yield
N/A
Revenue
$146.03M
Earnings
-$143.10M
Gross Margin
96.6%
Operating Margin
-81.46%
Profit Margin
-98%
Debt to Equity
-2.77
Operating Cash Flow
-$93M
Beta
1.43
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A

KPTI Overview

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KPTI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

KPTI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
KPTI is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
KPTI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more KPTI due diligence checks available for Premium users.

Be the first to know about important KPTI news, forecast changes, insider trades & much more!

KPTI News

Valuation

KPTI fair value

Fair Value of KPTI stock based on Discounted Cash Flow (DCF)
Price
$1.19
Fair Value
$1.57
Undervalued by
24.00%
KPTI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

KPTI price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.95x
Industry
15.19x
Market
36.17x

KPTI price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-1x
Industry
6.18x

KPTI's financial health

Profit margin

Revenue
$33.7M
Net Income
-$41.8M
Profit Margin
-124%
KPTI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
KPTI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$240.4M
Liabilities
$376.6M
Debt to equity
-2.77
KPTI's short-term assets ($233.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KPTI's long-term liabilities ($307.17M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KPTI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
KPTI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$18.6M
Investing
$26.8M
Financing
$264.0k
KPTI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

KPTI vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
KPTI$136.35M+2.16%-0.95x-1.00x
MOLN$136.60M-3.26%-2.05x0.63x
BCAB$136.62M+5.56%-1.07x1.44x
VTGN$137.02M-0.78%-1.48x1.11x
CYBN$137.76M-3.74%-1.62x1.53x

Karyopharm Therapeutics Stock FAQ

What is Karyopharm Therapeutics's quote symbol?

(NASDAQ: KPTI) Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol KPTI. Karyopharm Therapeutics stock quotes can also be displayed as NASDAQ: KPTI.

If you're new to stock investing, here's how to buy Karyopharm Therapeutics stock.

What is the 52 week high and low for Karyopharm Therapeutics (NASDAQ: KPTI)?

(NASDAQ: KPTI) Karyopharm Therapeutics's 52-week high was $4.87, and its 52-week low was $0.62. It is currently -75.67% from its 52-week high and 92.06% from its 52-week low.

How much is Karyopharm Therapeutics stock worth today?

(NASDAQ: KPTI) Karyopharm Therapeutics currently has 115,067,083 outstanding shares. With Karyopharm Therapeutics stock trading at $1.19 per share, the total value of Karyopharm Therapeutics stock (market capitalization) is $136.35M.

Karyopharm Therapeutics stock was originally listed at a price of $16.05 in Nov 6, 2013. If you had invested in Karyopharm Therapeutics stock at $16.05, your return over the last 10 years would have been -92.62%, for an annualized return of -22.94% (not including any dividends or dividend reinvestments).

How much is Karyopharm Therapeutics's stock price per share?

(NASDAQ: KPTI) Karyopharm Therapeutics stock price per share is $1.19 today (as of Mar 1, 2024).

What is Karyopharm Therapeutics's Market Cap?

(NASDAQ: KPTI) Karyopharm Therapeutics's market cap is $136.35M, as of Mar 3, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Karyopharm Therapeutics's market cap is calculated by multiplying KPTI's current stock price of $1.19 by KPTI's total outstanding shares of 115,067,083.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.